Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Core Insights - Incannex Healthcare Inc. has appointed Dr. Charlene E. Gamaldo to its IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, enhancing the company's expertise in sleep medicine [1][2] - The Phase 2 data readout for IHL-42X is expected next week, indicating the company's confidence in the asset and commitment to its development [2] - IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, currently in the RePOSA Phase 2/3 clinical trial, targeting obstructive sleep apnea by addressing its underlying pathophysiology [6][9] Company Overview - Incannex is focused on developing combination medicines for chronic conditions, including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [9][10] - The company is advancing three clinical-stage product candidates, with IHL-42X being the lead program designed to target the mechanisms of obstructive sleep apnea [9][10] - IHL-42X aims to benefit a broader range of patients, including the 67% of individuals with obstructive sleep apnea who are not classified as obese, addressing a significant gap in care [8] Clinical Development - The RePOSA Phase 2/3 clinical trial for IHL-42X is expected to enroll over 560 patients globally, with the Phase 2 portion conducted in the United States [6][7] - A topline readout from the U.S. Phase 2 portion is anticipated in July 2025, which will provide critical data on the efficacy of IHL-42X [7][8] - IHL-42X targets two key physiological pathways associated with obstructive sleep apnea, differentiating it from traditional weight loss therapies [8]